Monoclonal, Bispecific Antibodies and other complex molecules
Biologic drugs are the largest and fastest growing segment of the pharmaceutical industry with sales of €500bn and annual growth of 8%. Every manufacturing process for potential biologics begins with cell line development. Monoclonal antibodies (mAbs) have established themselves as the leading biopharmaceutical therapeutic modality. The establishment of robust manufacturing platforms is key for antibody drug discovery efforts to seamlessly translate into clinical and commercial successes. The accurate and reliable measurement of quality and quantity of protein is essential in development and manufacturing to ensure optimal cell culture performance for the production of all biologics.
Mesenchymal Stem Cells, Extracellular Vesicles and other cell-based therapies
The Cell Therapy sector has reached a critical point. Recent years have seen significant milestones reached with the approval of novel cell-based treatments for a wide array of diseases including certain cancers, degenerative conditions like osteoarthritis and immune disorders such as Crohn’s disease. Yet these ground-breaking therapies come with a hefty price tag and significant delivery challenges. To realise the promise shown by clinical trials, we must improve Cell Therapy manufacturing.